Pharmacokinetics & Metabolism

How EGCG is absorbed, metabolised, and limited by poor oral bioavailability in oncology use

EGCG is the main catechin in green tea, but its biggest practical limitation in oncology is poor oral bioavailability.

Bioavailability

Systemic oral bioavailability is very low.

Main reasons include:

poor stability in the intestinal environment
limited absorption
extensive first-pass metabolism
rapid conjugation and elimination

This is one reason EGCG may be more reliable for local gastrointestinal effects than for high systemic exposure using standard oral dosing.

Major metabolism pathways

EGCG is handled mainly through phase II pathways, including:

catechol-O-methyltransferase (COMT)
UDP-glucuronosyltransferases (UGT)
sulphotransferases (SULT)

CYP enzymes appear to play a secondary but still relevant role in practical interaction discussions.

CYP3A4 interaction relevance

EGCG is not mainly cleared through CYP3A4, but it still comes up in interaction discussions because it may inhibit CYP3A4 in preclinical systems.

Human data are more mixed, which is why it is best framed as a possible interaction modifier, not a predictable strong inhibitor in every real-world setting.

For a treatment-specific example, see Natural Compounds and CYP3A4 — HER2CLIMB Considerations.

Strategies that may improve exposure

fasting administration may improve absorption compared with fed use
liposomal and nanoparticle formulations may improve stability and delivery
dairy may reduce absorption because catechins bind proteins

Half-life and practical implication

EGCG has a relatively short half-life, which is one reason divided dosing often makes more sense than single-bolus use.

Key References

Epigallocatechin-3-gallate at the nanoscale: a new strategy to overcome barriers to anti-tumour activity
https://www.tandfonline.com/doi/full/10.1080/13880209.2024.2406779

Anticancer Molecular Mechanisms of Epigallocatechin-3-Gallate (EGCG)
https://onlinelibrary.wiley.com/doi/full/10.1002/fsn3.70735

Anticancer effects of epigallocatechin-3-gallate nanoemulsion on lung cancer cells
https://www.nature.com/articles/s41598-020-62136-2

This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use.